PwC’s IPO Lead On A Selective Market, AI Valuations And The Outlook For 2027
PwC IPO services leader Mike Bellin discusses the uneven U.S. initial public offering market rebound, investor demand for durable revenue, artificial intelligence valuations, and the outlook heading toward 2027.
The U.S. initial public offering market has mounted a rebound, though the recovery remains uneven. Enterprises attempting to go public encounter investors who are heavily focused on durable revenue, profitability, and proper valuation, while lingering market uncertainty has driven certain issuers to delay their offerings.
Mike Bellin, a partner and the U.S. IPO services leader at PricewaterhouseCoopers, observes a marketplace that stays open to companies possessing the appropriate scale, financial metrics, and preparation.
During a recent discussion with Crunchbase News, Bellin analyzed the cooling of IPO momentum, the methods public investors use to evaluate artificial intelligence entities, the revival of the biotech sector, and the reasons behind the renewed appeal of SPACs. Furthermore, he outlined the conditions required to establish a firmer foundation for early 2027.
This interview has been edited for length and clarity.
Crunchbase News: How healthy is the IPO market right now?
Bellin: A typical healthy IPO year in the United States generates anywhere from 125 to 175 traditional IPOs, and year to date we have recorded just under 90 or so.
The overall market breadth demonstrates that it has been a healthy environment. Industrial products have returned to the market alongside tech, consumer markets, energy, utilities, and select financial services.
For the majority of the first three quarters of the year, the IPO market was notably strong and broad. However, momentum has experienced a significant halt since September and October.
Is the market in trouble? I would argue no. It is simply very selective rather than closed. Quality issuers equipped with proper readiness, the right narrative, and accurate metrics are still successfully executing their deals.
What has contributed to the slowdown?
Bellin: The broader macroeconomic climate served as the primary driver: interest rates, inflation, and geopolitical concerns. General uncertainty played a major role.
Valuation has emerged as one of the most prominent factors I have witnessed. Certain transactions and offerings pursued fairly aggressive valuations, and considering the previously mentioned uncertainties, the market evaluated those price tags and deemed them somewhat excessive.
I believe numerous issuers chose to hit the pause button and wait for an alternative window to present itself.
What are public market investors looking for?
Bellin: Investors are primarily searching for durable revenue—revenue underpinned by robust, diverse customers and a growing top line. This dependable revenue stream, backed by a significant backlog of demand for the IPO issuer’s products and services, consistently signals strength.
Leverage represents the other critical consideration. For companies carrying substantial leverage within a rising-rate environment, the pressing questions are: Can they absorb new leverage that generates profitable value opportunities moving forward? Can they successfully refinance existing debt given higher interest rates?
Entering the capital markets with a sensible leverage ratio, or clearly articulating through your equity story how you achieve returns on capital invested via debt, makes a profound difference.
Is the market open to a broad range of venture-backed startups, or primarily larger companies?
Bellin: Scale matters. Companies possessing that scale—whether measured by revenue or asset base, depending on the industry sector—make a substantial difference. Those organizations can effectively dictate the window during which they launch and succeed.
Conversely, smaller companies, midmarket businesses, and smaller-cap entities—outside of life sciences and biotechs—have faced certain challenges.
If you are growing at an appropriate pace and demonstrating the right metrics, the IPO market remains fully accessible to those business models. Nevertheless, if you remain on the smaller side of the scale spectrum, your opportunities to access the market may be restricted.
Will enthusiasm for AI companies carry into public markets, or will investors be more skeptical?
Bellin: Investors are not inherently skeptical of AI; rather, they are skeptical of spending that lacks visibility—visibility regarding future earnings and the revenue durability I mentioned previously.
The market actively differentiates between AI companies with demonstrable demand and those relying strictly on a narrative, making demand, growth, and backlogs essential elements.
Another factor shaping today’s market centers on cash generation and profitability. If an enterprise is unprofitable, when will the profitable phase arrive? Profitability is measured in various ways, such as GAAP income, EBITDA, cash flows, free cash flows, and levered free cash flows accessible to the company.
We have never witnessed a development and growth cycle quite like this one before. It is thrilling, yet I anticipate the market will successfully discern which companies merit public status and which do not.
What does the uneven performance of newly public companies signal?
Bellin: It signals clear selectivity. While certain companies have emerged as massive winners in the IPO space, others have not traded as strongly post-issuance as many anticipated.
Numerous enterprises entering the market must carefully evaluate their pricing and valuation strategies. Attempting an overly aggressive pricing approach can lead to post-IPO trading declines, which in turn affect those key metrics.
On the whole, we observe strong candidates reaching the market. Given the existing volatility, companies appear to be arriving better prepared than ever before.
What is driving biotech’s resurgence?
Bellin: The merger and acquisition market for many of these firms is currently very robust. As prominent healthcare names lose patent protections on profitable drugs, they seek out the next generation of development and potential value creation.
A large portion of these biotechs were acquired by major pharmaceutical corporations prior to reaching the public markets. That competition for these assets and entities generates an advantageous trade-off between an IPO carrying high potential upside and an M&A exit offering immediate day-one certainty.
I view M&A as the underlying engine driving the biotech sector’s IPO revival.
Within the public offerings themselves, many of these assets have traded exceptionally well, creating a vital momentum and flywheel effect. We have witnessed this flywheel and momentum specifically within biotech, whereas the broader market has lacked it over recent months.
Why are SPACs attracting renewed interest?
Bellin: Market volatility has generated heightened discussion surrounding special purpose acquisition companies. Because SPACs establish valuation certainty on day one, an enterprise seeking an exit through a SPAC understands the potential cash inflow it might receive—though subject to variables like redemptions, of course.
Another factor fostering a healthy SPAC environment involves serial SPAC sponsors. These participants understand the SPAC vehicle, recognize the qualities of a strong de-SPAC candidate, and evaluate whether a target company is prepared to grow and hit milestones outlined in offering documentation.
Today’s market is healthier and more mature compared to previous years. Even so, a vast inventory of SPACs continues searching for target companies to acquire.
What do you expect in 2027?
Bellin: Hundreds of companies populate the pipeline, standing ready to launch whenever market conditions allow. The trajectory of the remainder of 2026 and the opening of 2027 depends heavily on market momentum.
I remain an eternal optimist. Buy-side demand is robust, and significant capital remains accessible to the right organizations. Therefore, establishing momentum through the final months of 2026 should pave the way for a strong start to 2027.
The artificial intelligence ecosystem we have discussed remains healthy. Energy demand continues to run high, attracting qualified energy enterprises to the market, while consumer and industrial products are staging a comeback.
Private equity maintained high activity levels throughout 2026, and I expect that engagement to persist into 2027.
We are positioned for a strong year ahead, though selectivity will remain the governing rule.
?Frequently Asked Questions
01What is an IPO market?
An initial public offering (IPO) market refers to the financial marketplace where private companies issue new stock to the public for the first time, transitioning into publicly traded corporations.
02Why are investors currently being selective with IPOs?
Amid macroeconomic uncertainties such as shifting interest rates, inflation, and geopolitical issues, investors are prioritizing companies that demonstrate durable revenue, reliable customer bases, clear profitability, and reasonable valuations.
03Why are SPACs seeing renewed interest?
SPACs offer valuation certainty on day one, allowing private companies to understand potential cash inflows despite variables like redemptions, drawing interest from experienced sponsors navigating market volatility.
04What is driving the biotech IPO resurgence?
The resurgence in biotech is largely fueled by strong merger and acquisition (M&A) activity, as major pharmaceutical companies look to acquire innovative pipelines to replace revenue lost from expiring drug patents.
Related Crunchbase query:
- Global IPOs For Venture-Backed Companies In 2026
Illustration: Dom Guzman
Thi Nien
Thi Nien is an AI, finance and global research analyst, specializing in global markets, macroeconomics, AI infrastructure, startups and emerging technologies. Her work focuses on analyzing the trends shaping the future economy, including artificial intelligence, institutional capital flows, digital assets and global financial innovation.
More from this author


